Research & Development, Medifast, Inc, Owings Mills, Maryland, USA.
Nutr J. 2010 Mar 11;9:11. doi: 10.1186/1475-2891-9-11.
Obesity has reached epidemic proportions in the United States. It is implicated in the development of a variety of chronic disease states and is associated with increased levels of inflammation and oxidative stress. The objective of this study is to examine the effect of Medifast's meal replacement program (MD) on body weight, body composition, and biomarkers of inflammation and oxidative stress among obese individuals following a period of weight loss and weight maintenance compared to a an isocaloric, food-based diet (FB).
This 40-week randomized, controlled clinical trial included 90 obese adults with a body mass index (BMI) between 30 and 50 kg/m2, randomly assigned to one of two weight loss programs for 16 weeks and then followed for a 24-week period of weight maintenance. The dietary interventions consisted of Medifast's meal replacement program for weight loss and weight maintenance, or a self-selected, isocaloric, food-based meal plan.
Weight loss at 16 weeks was significantly better in the Medifast group (MD) versus the food-based group (FB) (12.3% vs. 6.9%), and while significantly more weight was regained during weight maintenance on MD versus FB, overall greater weight loss was achieved on MD versus FB. Significantly more of the MD participants lost >or= 5% of their initial weight at week 16 (93% vs. 55%) and week 40 (62% vs. 30%). There was no difference in satiety observed between the two groups during the weight loss phase. Significant improvements in body composition were also observed in MD participants compared to FB at week 16 and week 40. At week 40, both groups experienced improvements in biochemical outcomes and other clinical indicators.
Our data suggest that the meal replacement diet plan evaluated was an effective strategy for producing robust initial weight loss and for achieving improvements in a number of health-related parameters during weight maintenance, including inflammation and oxidative stress, two key factors more recently shown to underlie our most common chronic diseases.
ClinicalTrials.gov NCT01011491.
肥胖已在美国达到流行程度。它与多种慢性疾病的发展有关,并与炎症和氧化应激水平的升高有关。本研究的目的是检查 Medifast 的代餐计划 (MD) 对减肥和体重维持期肥胖个体的体重、身体成分以及炎症和氧化应激生物标志物的影响,与等热量、基于食物的饮食 (FB) 进行比较。
这是一项为期 40 周的随机对照临床试验,纳入了 90 名 BMI 在 30 至 50kg/m2 之间的肥胖成年人,随机分配到两种减肥方案之一进行 16 周的减肥,然后进行 24 周的体重维持。膳食干预措施包括 Medifast 的代餐减肥和维持,或自我选择的等热量、基于食物的膳食计划。
16 周时,Medifast 组 (MD) 的体重减轻明显优于基于食物的组 (FB) (12.3%比 6.9%),尽管 MD 组在维持体重时体重明显增加,但总体而言,MD 组的体重减轻量大于 FB 组。在第 16 周和第 40 周时,更多的 MD 参与者体重减轻了初始体重的 >or= 5% (93%比 55%和 62%比 30%)。在减肥阶段,两组的饱腹感没有差异。在第 16 周和第 40 周时,与 FB 相比,MD 组的身体成分也有显著改善。第 40 周时,两组的生化结果和其他临床指标均有所改善。
我们的数据表明,评估的代餐饮食计划是一种有效的策略,可以在体重维持期间产生显著的初始体重减轻,并改善许多与健康相关的参数,包括炎症和氧化应激,这两个关键因素最近被证明是我们最常见的慢性疾病的基础。
ClinicalTrials.gov NCT01011491。